Cargando…

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir

Background: Ganciclovir and valganciclovir are used for prophylaxis and treatment of cytomegalovirus infection. However, there is great interindividual variability in ganciclovir’s pharmacokinetics (PK), highlighting the importance of individualized dosing. To facilitate model-informed precision dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Wenyu, Mak, Wenyao, Gwee, Amanda, Gu, Meng, Wu, Yue, Shi, Yufei, He, Qingfeng, Xiang, Xiaoqiang, Han, Bing, Zhu, Xiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386724/ https://www.ncbi.nlm.nih.gov/pubmed/37513988 http://dx.doi.org/10.3390/pharmaceutics15071801

Ejemplares similares

Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?
por: Mozaffar, Maryam, et al.
Publicado: (2018)

Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship
por: Galar, Alicia, et al.
Publicado: (2021)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir
por: Tripathy, Koushik, et al.
Publicado: (2017)

1703. Hematologic Toxicity of Valganciclovir Prophylaxis in Solid Organ Transplant Recipients as a Function of Weight-adjusted Ganciclovir Exposure
por: Campanella, Toni A, et al.
Publicado: (2020)

Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure
por: Jorga, Karin, et al.
Publicado: (2018)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
por: Cheng, Yu-Chun, et al.
Publicado: (2021)

Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method
por: Liu, Xin, et al.
Publicado: (2023)

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients
por: Perrottet, Nancy, et al.
Publicado: (2010)

P1336: ANTIVIRAL EXPOSURE TO GANCICLOVIR AND VALGANCICLOVIR IS NOT ASSOCIATED WITH INCREASED INCIDENCE OF RELAPSE OR SECONDARY MALIGNANCIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Duarte, D., et al.
Publicado: (2022)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
por: Gu, Meng, et al.
Publicado: (2023)

Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach
por: Lalagkas, Panagiotis Nikolaos, et al.
Publicado: (2023)

Applications of In Silico Models to Predict Drug-Induced Liver Injury
por: Lin, Jiaying, et al.
Publicado: (2022)

Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data
por: Murray, Jillian, et al.
Publicado: (2020)

Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children
por: Li, SiChan, et al.
Publicado: (2021)

Valganciclovir: Leucopenia: case report
Publicado: (2021)

Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients
por: Dvořáčková, Eliška, et al.
Publicado: (2022)

Retinal and Corneal Toxicity and Pharmacokinetic Analysis of Intraocular Injection of Ganciclovir in Rabbit Eyes
por: Sun, Bin-jia, et al.
Publicado: (2019)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease
por: Vezina, Heather E, et al.
Publicado: (2009)

A double masked randomised 4-week, placebo-controlled study in the USA, Thailand and Taiwan to compare the efficacy of oral valganciclovir and topical 2% ganciclovir in the treatment of cytomegalovirus anterior uveitis: study protocol
por: Takhar, Jaskirat S, et al.
Publicado: (2019)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
por: Stragliotto, Giuseppe, et al.
Publicado: (2020)

Mycophenolate-mofetil/valganciclovir: Neutropenia: case report
Publicado: (2022)

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

A desensitization protocol to ganciclovir
por: Cernadas, Josefina Rodrigues, et al.
Publicado: (2014)

Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function
por: Li, Anning, et al.
Publicado: (2023)

Synthesis, physicochemical properties and ocular pharmacokinetics of thermosensitive in situ hydrogels for ganciclovir in cytomegalovirus retinitis treatment
por: Wang, Qiyue, et al.
Publicado: (2017)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Development of an appropriate simple suspension method for valganciclovir medication
por: Masaoka, Yasuyuki, et al.
Publicado: (2020)

Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma
por: Pantalone, Mattia Russel, et al.
Publicado: (2022)

Crystallization after intravitreal ganciclovir injection
por: Choopong, Pitipol, et al.
Publicado: (2010)

Chronic Human Herpes Virus 8 Infection Successfully Treated With Valganciclovir
por: Yun, James J, et al.
Publicado: (2009)

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
por: Åsberg, A, et al.
Publicado: (2014)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

High Throughput Screening of Valganciclovir in Acidic Microenvironments of Polyester Thin Films
por: Schaller, Teilo, et al.
Publicado: (2015)

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation
por: Cheyssac, Elodie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f87f8b1np5q6q2q3ptbefupr0a